SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
DALLAS and FORT WORTH, Texas, Feb. 28, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
